Tempus AI

Tempus AI Gross Margin

The Gross Margin of Tempus AI (TEM) as of Nov 20, 2026 is 62.74 %. In the previous year, Gross Margin was 54.96 % — a change of 14.15% (higher).

Gross Margin

62.74 %

YoY

14.15%

Last updated:

Gross Margin of Tempus AI is 2025 62.74 % . Gross Margin of Tempus AI was 2024 54.96 % . It decreases by 14.15% higher compared to the previous year.

Tempus AI's gross margin stands at 62.7%, up from 32.4% several years earlier.

The Tempus AI Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2019
25.85 USD
Jan 1, 2020
15.27 USD
Jan 1, 2021
32.44 USD
Jan 1, 2022
40.60 USD
Jan 1, 2023
53.81 USD
Jan 1, 2024
54.96 USD
Jan 1, 2025
62.74 USD
The Tempus AI Gross Margin history
YEARGross MarginYoY
62.74 %+14.15%
54.96 %+2.14%
53.81 %+32.54%
40.60 %+25.15%
32.44 %+112.39%
15.27 %-40.92%
25.85 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tempus AI Stock analysis

What does Tempus AI do? Tempus AI Inc provides next generation diagnostics through genomics, data, and AI applications. Its genomics product line includes next generation sequencing, diagnostics, PCR, profiling, molecular genotyping, and pathology testing. The AI applications focus on algorithmic diagnostics, software as a medical device, and clinical decision support tools. The primary AI product Next uses machine learning to identify care gaps for oncology and cardiology patients. The company serves healthcare providers and life sciences organizations seeking personalized medicine solutions. Tempus AI Inc's revenue comes from its genomics and AI product lines. The genomics services are delivered through its laboratories, offering sequencing, diagnostics, and molecular testing. The AI applications, particularly Next, are sold as software solutions to healthcare institutions. The target customers are healthcare providers and life sciences companies that require advanced diagnostic tools for personalized treatment plans. The company operates in the Life Sciences Tools & Services industry, focusing on oncology and cardiology segments. The company's genomics product line generates revenue through laboratory services for molecular pathology testing. AI applications like Next are sold as medical device software, targeting healthcare institutions for clinical decision support. The primary segments served are oncology and cardiology, where personalized medicine is critical. The company's products are designed to integrate with existing healthcare data systems to improve patient care outcomes. Tempus AI is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tempus AI stock

Gross Margin of Tempus AI is 62.74 % in 2025.

Gross Margin of Tempus AI changed from 54.96 % to 62.74 %, representing a 14.15% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Tempus AI since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Tempus AI with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Tempus AI

All Key Metrics — Tempus AI